Immunoscore, molecular profile, and their correlation with the clinical outcomes of a series of 15 thymic carcinomas were evaluated. We confirmed the low rate of mutations in thymic carcinomas and suggest FGFR3 and CDKN2A mutations as intriguing potential therapeutic targets

Subxifoid thoracoscopy is a safe procedure compared to conventional transthoracic thoracoscopy. It avoids intercostal incision and spares nerve trauma, resulting in a reduction of postoperative pain and paresthesia.

CITED4 expression is significantly upregulated in ADC tissues and cells. CITED4 interacted with CTNNB1 and functioned synergistically to enhance CLDN3 transcription. The CITED4-CTNNB1-CLDN3 axis plays a key role in the invasion and metastasis of ADC and provides a novel therapeutic target for lung cancer treatment.

Our results suggested that LOC101928477 could be a novel suppressor gene involved in ESCC progression.

The expression levels of hsa_circ_0001173, hsa_circ_0007291, hsa_circ_0003550, and hsa_circ_0001947 were significantly upregulated and positively correlated with immune imbalance in thymoma patients. The discovery of new differentially expressed circRNAs can be used not only as a biomarker for diagnosis, but also as a potential target for the treatment of thymoma.

Forty-five patients with stage III non-small cell lung cancer (14 stage IIIA, 31 stage IIIB) who received high-dose (74 GyE) passive-scattering proton beam therapy (PBT) with concurrent chemotherapy were retrospectively reviewed to analyze survivals and toxicities. The 3- and 5-year overall survival rates were 63.7% and 38.8%, respectively, and the median overall survival was 49.1 months. Passive-scattering PBT of 74 GyE with chemotherapy showed favorable survival and a low incidence of severe adverse events in patients with stage III NSCLC.

Here, we report the largest analysis of clinical characteristics of thymomas and outcomes in Latin American patients. Out of 135 patients included in the study, 21.5% (n = 29) concurrently presented myasthenia gravis. Relapse-free survival rates at five-years were 58.5% for stage I–II, and 35.4% for stage III. Five-year overall survival rates were 73.4%, 63.8% and 51%, at stages I–II, III–IVA and IVB, respectively.

Pathologic response and nodal status of 194 nonsmall-cell lung cancer patients who received neoadjuvant chemotherapy and surgery were investigated. We demonstrated that major pathologic response was not adequate to predict survival, but when combined with nodal downstaging it could improve the efficacy of predicting survival in these patients. This helped to identify the population subset with the most favorable prognosis.

We found that biglycan (BGN) is expressed in tumor endothelial cells (TECs) and that BGN expression in TECs is associated with tumor progression and prognosis in lung cancer. Moreover, BGN expression in preoperative serum was significantly associated with BGN expression in TECs and with tumor malignancy.

With a median follow-up of 25 months, no significant differences were found in cardiac-related mortality between the PORT and Non-PORT groups in stage IIIA-N2 NSCLC patients. The overall incidence of cardiac-related mortality was decreased over time.

This retrospective study evaluated the prognostic value of the geriatric nutritional risk index (GNRI) among patients with previously treated advanced non-small cell lung cancer (NSCLC) who subsequently underwent immunotherapy. A high GNRI was associated with good outcome among patients with NSCLC. These results can be applied in clinical practice to evaluate patient prognosis and response to therapy.

In this open-label, multicentre, phase 2 trial, anti-PD-L1 antibody (SHR-1316) plus liposomal irinotecan and 5-fluorouracil resulted in an impressive median progression-free survival of 8.5 months, median overall survival of 11.6 months, objective response rate of 52.2%, disease control rate of 73.9%, and median duration of response of 11.2 months. Adverse events were also manageable.

After the introduction of thoracic duct embolization (TDE), only three of 48 patients underwent surgical ligation of thoracic duct. The length of hospital stay of patients who underwent lung cancer surgery was shorter than that before the introduction of TDE. This study demonstrated that TDE is an effective method for the management of postoperative chyle leakage and can help avoid invasive surgery in this group of patients.

There was no significant difference in clinical response and prognosis between the combination therapy group and the monotherapy group. We think that the higher frequency of treatment discontinuation due to adverse events in the combination therapy group compared to the monotherapy group is one reason why there was no significant difference in prognosis between the two groups.

1. A modified inflation-deflation method is a simple technique for distinguishing the intersegmental demarcations. 2. Nitrous oxide is an inhaled anesthetic gas with high gas solubility, which could accelerate the process of lung collapse. 3. A combination of nitrous oxide and the modified inflation-deflation method can quickly and accurately identify lung resection borders.

The present study substantiated that quercetin induces pro-apoptotic autophagy via SIRT1/AMPK signaling pathway in human lung cancer cell line A549 in vitro. Furthermore, our study might provide a more effective therapeutic strategy for lung cancer by a combination treatment with quercetin and autophagy agonist.

Expanding the TNM by integrating additional factors/variables is challenging. This study used machine learning to create prognostic systems that expand the TNM. On the basis of primary tumor, regional lymph nodes, metastasis, age, and histology type, a prognostic system for lung cancer was created to improve the patient stratification and survival prediction of the TNM.

The learning curve of RPL-4 can be divided into three phases. Ten cases were required to pass the learning curve, but the mastery of RPL-4 for satisfactory surgical outcomes requires experience from at least 56 cases.

We report a case involving a patient with epidermal growth factor receptor-mutant lung adenocarcinoma and antisynthetase syndrome accompanied by interstitial lung disease (ILD), treated with osimertinib. After steroid pulse therapy, osimertinib was administered for the lung adenocarcinoma, without ILD exacerbation. Osimertinib could be a treatment option for EGFR-mutant lung cancer with paraneoplastic ILD.

Isodose distribution of the patient receiving total dose of 60 Gy of SBRT in three dimensions of computed tomography.

Here, we report for the first time somatic mutations between the epithelium of IPF and LC sites detected by NGS using a laser-assisted microdissection technique. Almost all somatic mutations did not overlap between the IPF and LC regions.

Angiomatoid fibrosis histiocytoma (AFH) is a rare neoplastic disease. Only one report has demonstrated an intraluminal tumor of the pulmonary artery trunk corresponding to AFH with ESWR1-ATF1 fusion to date. This is the first reported case of AFH occurring in the ascending artery with EWSR1-CREB1 fusion.

We present a case of an elderly patient with non-small cell carcinoma with underlying idiopathic pulmonary fibrosis (IPF) who was treated with nintedanib. After seven months, partial remission of the lung cancer was observed without progression of IPF. This report indicates the possibility that nintedanib monotherapy could suppress lung cancer in patients with IPF.

Thoracoscopic intrapericardial lingulectomy following immunotherapy can be safely performed even in the presence of pulmonary hilar fibrosis.

Endoscopic ultrasound with bronchoscope-guided fine-needle aspiration (EUS-B-FNA), a minimally invasive procedure, may be useful for the diagnosis of pseudomesotheliomatous (PMC) carcinoma because a sufficient amount of tissue can be obtained for diagnosis. This is the first report of PMC diagnosed using EUS-B-FNA. Our findings suggest that EUS-B-FNA may reduce the risk of dissemination for PMC.

The unique radiological manifestation mimicking autoimmune pancreatitis caused by lung cancer metastasis to the pancreas has not previously been reported. The incidence of pancreatic secondary tumors has previously been reported to be approximately 15% in autopsy cases of malignant tumors, and it is unusual for thoracic oncologists to find that the second common primary tumor site of metastatic pancreas tumor is the lung.

Perioperative irAE management is an important part of immune perioperative treatment of lung cancer. With the continuous development of immune perioperative treatment, more research is needed in the future to optimize the diagnosis and treatment of perioperative irAE.

Calcified or inflammatory lymph nodes between the target bronchus and pulmonary artery is a huge challenge when performing thoracoscopic lobectomy. Here, we report a strategy to handle this clinical situation. A needle was passed across the nodes and the target vessel was closed with a proximal and distal suture, and then gradually transected with scissors. After dissection of adenopathies, the target bronchus was stapled.